BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $5.83, for a total value of $46,640.00. Following the transaction, the director now owns 572,754 shares in the company, valued at approximately $3,339,155.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ BDSI opened at $5.80 on Friday. The firm has a market cap of $519.23 million, a P/E ratio of -7.95 and a beta of 0.39. The company has a current ratio of 2.34, a quick ratio of 2.09 and a debt-to-equity ratio of 0.88. BioDelivery Sciences International, Inc. has a 1-year low of $2.80 and a 1-year high of $6.12. The business’s 50 day moving average is $5.06 and its 200-day moving average is $4.56.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative return on equity of 0.85% and a negative net margin of 34.73%. The firm had revenue of $29.68 million for the quarter, compared to analyst estimates of $25.30 million. Analysts forecast that BioDelivery Sciences International, Inc. will post -0.05 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in BioDelivery Sciences International by 277.2% during the 2nd quarter. BlackRock Inc. now owns 5,498,457 shares of the specialty pharmaceutical company’s stock worth $25,568,000 after acquiring an additional 4,040,621 shares during the period. Vanguard Group Inc. increased its stake in BioDelivery Sciences International by 30.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,395,428 shares of the specialty pharmaceutical company’s stock worth $15,788,000 after acquiring an additional 793,179 shares during the period. Stonepine Capital Management LLC increased its stake in BioDelivery Sciences International by 79.6% during the 2nd quarter. Stonepine Capital Management LLC now owns 2,764,475 shares of the specialty pharmaceutical company’s stock worth $12,855,000 after acquiring an additional 1,225,038 shares during the period. Emerald Advisers LLC increased its stake in BioDelivery Sciences International by 11.4% during the 3rd quarter. Emerald Advisers LLC now owns 2,084,685 shares of the specialty pharmaceutical company’s stock worth $8,777,000 after acquiring an additional 212,553 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its stake in BioDelivery Sciences International by 13.8% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,944,531 shares of the specialty pharmaceutical company’s stock worth $8,186,000 after acquiring an additional 236,254 shares during the period. Hedge funds and other institutional investors own 66.54% of the company’s stock.

A number of brokerages have recently weighed in on BDSI. ValuEngine upgraded BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 29th. William Blair reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Tuesday, September 17th. Finally, BidaskClub lowered BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $6.20.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: Arbitrage

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.